Regulatory Status AOD-9604 is not FDA-approved for any medical use and is listed by the FDA as a bulk drug substance that may present safety risks. Clinical development was halted after Phase IIb trials failed to meet efficacy endpoints. Summary AOD-9604 is a synthetic analog of the HGH 177191 fragment developed for fat-metabolism research
After an injury ended his Navy SEAL training, he shifted to personal training, discovered functional lab testing, and became a leading expert in metabolic health
The natural instinct is to throw the product away
Data from 5,916 CKD patients participating in the NHANES study indicated that those who adhered to physical activity guidelines (150 minutes of moderate-intensity physical activity per week) had better albumin-to-creatinine ratios and a 51% lower risk of death from any cause during 10 years of follow-up
PharmaLabGlobal Australia peptide pens are pre-loaded with the correct reconstitution of peptides, removing the need for manual measurement or mixing, therefore reducing the risk of error and ensuring correct dosing every time